Association of Serum Osteocalcin with Insulin Resistance and Coronary Atherosclerosis

Kang, Jee Hyun

doi:10.11005/jbm.2016.23.4.183

Cited by 13 publications

(13 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Week a b c Vitamin K is necessary to carboxylate osteocalcin and deficiency results in increased risk of fracture. 2,3,7,25 An analysis of blood samples from 896 persons suggested that most people do not receive enough vitamin K from their diet (32). 26 The best vitamin K to improve vitamin K status is long-chained MKs.…”

Section: Discussionmentioning

confidence: 99%

“…Beside its role in bone tissue osteocalcin is a hormone affecting diverse functions such as metabolism, adaptation to exercise and brain function. 2,3,5,7 In mice, these effects have been attributed to undercarboxylated osteocalcin, but in several human studies osteocalcin or only carboxylated osteocalcin rather than the undercarboxylated have shown effects. [30][31][32][33] The present results indicate intake of Jarlsberg ® cheese to cause both carboxylated and under carboxylated osteocalcin to increase.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Increased serum osteocalcin levels and vitamin K status by daily cheese intake

Lundberg¹,

Holand

Holo

et al. 2020

Int J Clin Trials

View full text Add to dashboard Cite

Background: Cheese is a major source of long-chained vitamin K2 variants. How intake of vitamin K2 rich cheese affects vitamin K and osteocalcin has not been studied. The aim was to establish a maximum efficacy dose (MED) after daily intake of vitamin K2-rich cheese (Jarlsberg®) based on increase in ratio between carboxylated and undercarboxylated osteocalcin during a five-week diet.Methods: 20 healthy healthy volunteers (HV) were recruited. The daily intake of Jarlsberg® cheese in the study varied from 20 to 152 g. Clinical investigation was performed initially and after three, four and five weeks with measurement of vital signs, hematological and biochemical variables, carboxylated and undercarboxylated osteocalcin and vitamin K. The ratio OR= carboxylated/undercarboxylated osteocalcin was the main variable.Results: The MED decreased with treatment duration and was estimated to 57 g/day (95% CI: 47-67) after five weeks diet, resulting in a mean OR increase of 30% (95% CI: 23.8-36.8). Both OR and serum osteocalcin followed a quadratic dose response curve. For osteocalcin, a maximal increase of 46% was estimated at 59 g/day for five weeks. The serum content of long-chained vitamin K2 increased significantly with increasing cheese dose. The increase were mainly obtained the first three weeks and kept unchanged the following two weeks. The cheese doses close to the MED caused nearly significant reductions in total cholesterol, LDL-cholesterol, the LDL/HDL ratio and significant reduction in the blood pressures after five weeks diet (p≤0.05).Conclusions: MED of Jarlsberg® cheese was estimated to 57 g/day. Daily intake of Jarlsberg® cheese increased the osteocalcin level, vitamin K2 and positively affected the lipid patterns and blood pressure.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Increased serum osteocalcin levels and vitamin K status by daily cheese intake

Lundberg¹,

Holand

Holo

et al. 2020

Int J Clin Trials

View full text Add to dashboard Cite

show abstract

“…In general, the association of cytokines (e.g., osteocalcin) with bone metabolism and growth is known and is to be expected [28]. Here, we added data on sclerostin and osteoprotegerin as independent predictors of height SDS.…”

Section: Discussionmentioning

confidence: 99%

The Bone Markers Sclerostin, Osteoprotegerin, and Bone-Specific Alkaline Phosphatase Are Related to Insulin Resistance in Children and Adolescents, Independent of Their Association with Growth and Obesity

et al. 2019

View full text Add to dashboard Cite

Background/Aims: Sclerostin, osteoprotegerin, and bone-specific alkaline phosphatase (B-ALP), which are primarily related to bone metabolism, have been linked with insulin resistance in adults. We aimed to evaluate the association of these markers with growth, obesity, and parameters of insulin resistance in lean and obese children and adolescents. Methods: We measured sclerostin, osteoprotegerin, and B-ALP in fasting and oral glucose tolerance test (oGTT) serum samples from 1,325 children and adolescents, and during 24-h profiles and after exercise and glucose exposure in young adults. Results: In addition to the positive relationship with height standard deviation scores (SDS), sclerostin (r = 0.035, p < 0.001) and B-ALP (r = 0.06, p = 0.028) increased, whereas osteoprotegerin (r = –0.098, p < 0.001) decreased with BMI SDS. Furthermore, B-ALP correlated with fasting- and oGTT-derived markers of glucose and insulin metabolism suggestive of insulin resistance. To evaluate potential confounding diurnal variation of bone markers, we performed 24-h profiles. B-ALP and osteoprotegerin had lower night-time levels. Exercise acutely and transiently increased B-ALP and osteoprotegerin levels, but glucose ingestion had no effect. Conclusions: Besides their association with growth, sclerostin and osteoprotegerin levels are altered in childhood obesity. Particularly B-ALP was related to insulin resistance indices. Our findings accent the link between bone, growth, and insulin resistance.

show abstract

“…Serum osteocalcin levels in women with T2DM are lower compared with nondiabetic women [17,18]. Moreover, there is an inverse association between serum osteocalcin levels and both fasting glucose levels and insulin resistance [19]. Incretins have also been implicated in the pathogenesis of increased fracture risk in patients with T2DM.…”

Section: T2dm and Fracturesmentioning

confidence: 99%

Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk

Erythropoulou-Kaltsidou

Polychronopoulos

Τζιόμαλος

2019

Diabetes Ther

View full text Add to dashboard Cite

Patients with type 2 diabetes mellitus (T2DM) appear to have increased risk for fractures. In this context, the finding that canagliflozin, a sodiumglucose co-transporter-2 (SGLT) inhibitor, increased the risk for fracture compared with placebo in the Canagliflozin Cardiovascular Assessment Study (CANVAS), a large randomized controlled trial (RCT) in patients with established cardiovascular disease or multiple cardiovascular risk factors, created concern. In the present review, we summarize the data regarding the association between SGLT2 inhibitors and fracture risk in patients with T2DM. In contrast to the findings reported in CANVAS, canagliflozin did not affect the risk of fracture in a more recent, large RCT in patients with diabetic nephropathy. In addition, empagliflozin and dapagliflozin, other members of this class, also do not appear to affect the incidence of fracture. Moreover, there is no clear pathogenetic mechanism through which SGLT2 inhibitors increase the risk for fractures. Therefore, available data are inconclusive to attribute to these drugs a direct responsibility for bone fractures.

show abstract

Association of Serum Osteocalcin with Insulin Resistance and Coronary Atherosclerosis

Cited by 13 publications

References 33 publications

Increased serum osteocalcin levels and vitamin K status by daily cheese intake

Increased serum osteocalcin levels and vitamin K status by daily cheese intake

The Bone Markers Sclerostin, Osteoprotegerin, and Bone-Specific Alkaline Phosphatase Are Related to Insulin Resistance in Children and Adolescents, Independent of Their Association with Growth and Obesity

Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk

Contact Info

Product

Resources

About